Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue 3, 2013, Pages 174-184

  Chadda, Rakesh ^a   Ramshankar, Prashanth ^a   Deb, Koushik ^a   Sood, Mamta ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antipsychotic; metabolic syndrome; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; TIOTIXENE; ZIPRASIDONE;

AGE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG CHOICE; DRUG SAFETY; DYSGLYCEMIA; DYSLIPIDEMIA; ETHNIC DIFFERENCE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HISPANIC; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; POLYPHARMACY; PREVALENCE; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84881128987     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.114596     Document Type: Review

References (97)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31
3. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010;196:116-21
4. Heiskanen T, Niskanen L, Lyytikinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9
5. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1-30
6. Davis JM, Chen N. Old versus new: Weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry 2005;20:7-14
7. Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: Comparative effectiveness of first-generation versus second-generation medications: A systematic review and meta-Analysis. Ann Intern Med 2012;157:498-511
8. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6
9. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, et al. Metabolic profile of antipsychotic-naive individuals with non-Affective psychosis. Br J Psychiatry 2009;194:434-8
10. Lieberman JA 3rd. Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 2004;6(Suppl 2):8-13
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
12. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
14. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: A new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80
15. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004;47:S76-9
16. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9
17. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007;24:481-5
18. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164:1557-60
19. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 2009;70:997-1000
20. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495
21. Gunnell D, Holly JM. Do insulin-like growth factors underlie associations of birth complications, fetal and pre-Adult growth with schizophrenia? Schizophr Res 2004;67:309-11
22. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 2004;184:58-62
23. Arranz B, Rosel P, Ramrez N, Dueas R, Fernndez P, Sanchez JM, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004;65:1335-42
24. McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: Case-control study. BMJ 1998;317:784-5
25. Sengupta S, Parrilla-Escobar MA, Klink R, Fathalli F, Ng YK, Stip E, et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr Res 2008;102:329-36
26. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never treated chronic schizophrenia. Schizophr Res 2010; 121: 199-202
27. Grover S, Nebhinani N, Chakrabarti S, Parakh P, Ghormode D. Metabolic syndrome in antipsychotic nave patients diagnosed with schizophrenia. Early Interv Psychiatry 2012;6:326-31
28. Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, et al. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull 2009;35:437-42
29. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41
30. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999-2008
31. Pallava A, Chadda RK, Sood M, Lakshmy R. Metabolic syndrome in schizophrenia: A comparative study of antipsychotic-free/nave and antipsychotic-treated patients from India. Nord J Psychiatry 2012;66:215-21
32. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 2009;111:9-16
33. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008;101:295-303
34. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: A six-week prospective study in Indian female patients. Schizophr Res 2007;95:247
35. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007;41:606-10
36. Mattoo SK, Mohan Singh S. Prevalence of metabolic syndrome in psychiatric inpatients in a tertiary care centre in north India. Indian J Med Res 2010;131:46
37. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamashita H, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010;123:244-50
38. Cohn T, Prudhomme D, Streiner D, Kameh H, Remington G. Characterizingcoronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60
39. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004;6:74-7
40. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
41. Hgg S, Lindblom Y, Mjrndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8
42. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jrvelin MR, Laurn LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-63
43. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006;21:S11-5
44. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-6
45. Bai YM, Chen JY, Yang WS, Chi YC, Liou YJ, Lin CC, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry 2007;68:1834-9
46. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 2007;90:162-73
47. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330-6
48. Sanchez-Arana Moreno T, Tourio Gonzlez R, Hernndez Fleta JL, Len Prez P. Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands. Actas Esp Psiquiatr 2007;35:359-67
49. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008;38:103-12
50. Cerit C, Ozten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg 2008;19:124-32
51. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10:788-97
52. Lee E, Leung CM. Atypical antipsychotics and metabolic outcomes in Chinese patients: A comparison of olanzapine and risperidone. J Clin Psychopharmacol 2008;28:707-9
53. Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study. Schizophr Res 2009;111:1-8
54. Brunero S, Lamont S, Fairbrother G. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 2009;23:261-8
55. John AP, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176-9
56. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009;120:274-80
57. Rezaei O, Khodaie-Ardakani MR, Mandegar MH, Dogmehchi E, Goodarzynejad H. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. Int J Psychiatry Med 2009;39:451-62
58. Yazici MK, Anil Ya?cio?lu AE, Ertu?rul A, Eni N, Karahan S, Karaa?ao?lu E, et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: Findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 2011;261:69-78
59. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18
60. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005;162:947-53
61. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
62. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085-97
63. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007;68:1733-40
64. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia-A randomized double-blind controlled, short-term prospective study. Schizophr Res 2008;101:266-72
65. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: A naturalistic one-year follow-up study. BMC Psychiatry 2007;7:14
66. Suvisaari JM, Saarni SI, Perl J, Suvisaari JV, Hrknen T, Lnnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-55
67. Hgg S, Joelsson L, Mjrndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-9
68. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100
69. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008;103:104-9
70. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. The METEOR study: Frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011;26:291-302
71. Amdisen A. Diabetes mellitus as a side effect of treatment with tricyclic neuroleptics. Acta Psychiatr Scand 1964;40(Suppl 180):411+
72. Harris E, Eth S. Weight gain during neuroleptic treatment. Int J Nurs Stud 1981;18:171-5
73. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968;124:978-82
74. Brambilla F, Guastalla A, Guerrini A, Riggi F, Rovere C, Zanoboni A, et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976;37:98-103
75. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 2001;34:223-31
76. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-65
77. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999;60:783-91
78. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-81
79. Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998;21:245-50
80. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975-81
81. Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Ir Med J 2002;95:119-20
82. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: The effect of concurrent beta-Adrenergic antagonist treatment. Schizophr Res 2003;59:49-57
83. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-40
84. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
85. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001;158:1719-22
86. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83
87. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005;162:118-23
88. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006;186:572-8
89. Sengupta SM, Klink R, Stip E, Baptista T, Malla A, Joober R. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr Res 2005;80:131-3
90. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
91. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
92. Hirsch SR, Kissling W, Buml J, Power A, OConnor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-23
93. Leucht S, Wagenpfeil S, Hamann J, Kissling W. Amisulpride is an "atypical" antipsychotic associated with low weight gain. Psychopharmacology (Berl) 2004;173:112-5
94. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
95. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19:1-93
96. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008;104:1-12
97. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003;60:99-100